APA (7th ed.) Citation

BH, O., SM, L., RT, M., CR, T., JD, R., NG, A., . . . MR, G. (2026). Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial. MedRxiv : the preprint server for health sciences. https://doi.org/10.64898/2026.06.22.26354817

Chicago Style (17th ed.) Citation

BH, Ozer, et al. "Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial." MedRxiv : The Preprint Server for Health Sciences 2026. https://doi.org/10.64898/2026.06.22.26354817.

MLA (9th ed.) Citation

BH, Ozer, et al. "Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial." MedRxiv : The Preprint Server for Health Sciences, 2026, https://doi.org/10.64898/2026.06.22.26354817.